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incidence and epidemiology
Two different primary malignancies can arise from the adrenal
gland: the adrenocortical carcinoma (ACC) from the adrenal
cortex and the malignant pheochromocytoma from the adrenal
medulla. Both malignancies are extremely rare. ACC has an
estimated incidence of ∼0.5–2 new cases per million people
per year. It follows a bimodal age distribution, with peaks in
childhood and in the fourth to ﬁfth decades of life. ACC is
more frequent in women than in men (ratio 1.5∶1). The
majority of ACCs are sporadic; however, sometimes these
malignancies form part of hereditary syndromes such as the
Li-Fraumeni syndrome, Beckwith-Wiedeman syndrome,
multiple endocrine neoplasia (MEN) 1, congenital adrenal
hyperplasia, familial polyposis coli, and B-catenin mutations
[1]. Germline p53 mutations without Li-Fraumeni are frequent
in southern Brazilian children.
The frequency of sporadic ACC cases is consistently greater
in the population of patients with adrenal incidentaloma (2%
in the most conservative series) and, in our experience, the
proportion of incidentally discovered ACC is increasing.
Pheochromocytomas are catecholamine-producing
neuroendocrine tumors arising from chromafﬁn cells of the
adrenal medulla or extra-adrenal paraganglia. In the latter
setting, the term paraganglioma is preferred. Their incidence is
∼2–8 per million adults per year [2]. The incidence of
pheochromocytoma increases to 0.5% in patients with
hypertensive symptoms and can be as high as 4% in patients
with adrenal incidentalomas. Up to 30% of
pheochromocytomas are associated with a variety of inherited
conditions, including MEN2, Von Hippel–Lindau (VHL)
disease, neuroﬁbromatosis type 1, and heredity paraganglioma
syndromes. Only a few (10%–17%) pheochromocytomas are
malignant. Although the likelihood of malignancy varies
among different genetic backgrounds, it is below 10% for most
sporadic pheochromocytomas, except in patients with
mutations in the succinate dehydrogenase B (SDHB) gene and/
or extra-adrenal locations, among whom more than 30%–50%
may develop a malignant tumor.
diagnosis and pathology/molecular
biology
Somatic mutations of the tumor suppressor gene TP53 are
observed in one-third of ACCs. In addition, allelic losses
(LOH) at the TP53 locus (17p13) are observed in >85% of
ACCs. The insulin-like growth factor II (IGF-II) locus (11p15)
is imprinted and IGF-II is overexpressed in 90% of ACCs.
About one-third of ACCs harbor somatic activating mutations
of the B-catenin gene [3].
The gene encoding subunit B of the SDHB complex is by far
the most important contributor to a hereditary malignant
pheochromocytoma/paraganglioma. In addition, many
sporadic metastatic pheochromocytomas/paragangliomas have
similar molecular proﬁles to those of hereditary tumors.
Inactivation of mutations in SDHB is thought to reduce
function of the SDHB complex, causing a pseudohypoxic state
and increased expression of angiogenic, growth and mitogenic
factors via stabilization of the hypoxia-inducible pathway. If no
SDHB mutations are identiﬁed, genetic testing for VHL,
SDHD, or succinate dehydrogenase C (SDHC) is indicated and
may provide future insights into the best therapeutic options to
be developed for these patients [2]. Rearranged during
transfection (RET) should be tested in case of calcitonine
secretion and may be tested when all other gene mutations are
negative.
A detailed preoperative endocrine assessment is essential to
establish the origin of the tumor (cortex versus medulla
versusothers). In all cases of an adrenal mass a comprehensive
hormonal analysis is strongly recommended. In 2005, the ACC
working group of the European Network for the Study of
Adrenal Tumors (ENSAT; www.ensat.org) proposed standards
for this situation in patients with suspected or established ACC
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(Table 1). It is important to acknowledge that the evidence
level for this proposition is formally low, although the
diagnostic accuracy is high (V, B). Furthermore, the
preoperative hormone pattern may serve as a ﬁngerprint of the
tumor during follow-up. Whereas the measurement of
metanephrine and normetanephrine is well established for any
pheochromocytoma, plasma and urine methoxytyramine levels
that provide useful information to assess the likelihood of
malignancy [4]. However, this marker is not yet widely
available.
Urine steroid metabolomics revealed a pattern of nine
predominantly immature, early-stage steroidogenesis in ACC
that performed well in differentiating adenomas from ACCs.
The use of this technique in clinics is, however, premature [5].
For best patient care, adequate visualization of the tumor
and potential metastases is essential. For differential diagnosis
of an adrenal mass computed tomography (CT) and magnetic
resonance imaging (MRI) are currently considered equally
effective. CT is less expensive and should be recommended as
the ﬁrst choice in a suspected ACC. Conversely, MRI offers a
preferential application for the suspicion of
pheochromocytoma due to the risk of a hypertensive crisis
after infusion of i.v. contrast medium for CT. Although these
methods cannot determine the exact entity of the mass, both
are able to correctly diagnose benign tumors in most cases—
when performed according to the state-of-the-art criteria (e.g.
Hounsﬁeld units <10 in unenhanced CT, rapid washout in 15-
min delayed contrast-enhanced CT or signal intensity loss
using opposed-phase MRI strongly suggests a benign tumor).
Most ACCs and malignant pheochromocytomas are
inhomogeneous with irregular margins and irregular
enhancement of solid components after the infusion of i.v.
contrast medium and, in many cases, it is difﬁcult to
distinguish these tumor entities using conventional imaging.
The detection of local invasion or tumor extension into the
inferior vena cava, as well as lymph node or other
metastases (lung and liver), is important for planning
surgery. F-18/ﬂourodeoxyglucose-positron emission
tomography (FDG-PET) is a useful tool for distinguishing
potentially malignant lesions from benign tumors in
radiologically indeterminate adrenal lesions. In patients with
established pheochromocytoma, FDG-PET appears to be
superior to metaiodobenzylguanidine (MIBG) and
somatostatin- or F-dopamin-based methods, particularly in
patients with SDHB mutation and malignant tumors, and
should be indicated as the preferred method [6] (IV).
Fine needle biopsy of a suspected ACC is almost never
justiﬁed because of anticipated tumor spill, and in suspected
pheochromocytoma, it is contraindicated.
The pathological differential diagnosis of adrenal neoplasias
is still largely based on morphological features requiring an
experienced pathologist. Several markers have been introduced
to establish the adrenocortical origin of adrenal masses, with
steroidogenesis factor-1 immunohistochemistry being
particularly useful [7], although not yet widely available. The
differential diagnosis between carcinoma and adenoma is
challenging as no single marker indicates malignancy. The
most widely used diagnostic score has been introduced by
Weiss et al. [8] and includes the following parameters: mitosis,
atypical mitosis, necrosis, venous invasion, sinusal invasion,
capsular invasion, nuclear atypia, diffuse architecture, and clear
cell. A score of ≥3 suggests malignancy. Ki67 as a marker of
proliferative activity can also be useful in this respect.
For pheochromocytomas, the situation is similarly
demanding. Several histologic features (local invasiveness,
growth pattern, presence of necrosis, cellularity, spindled
morphology, nuclear pleomorphism and hyperchromasia,
mitotic activity, and atypical mitosis) comprise the
Pheochromocytoma Adrenal gland Scaled Score. However,
there is currently no consensus on the adoption of a formal
scoring system for these tumors [2]. According to the current
World Health Organization (WHO) classiﬁcation, malignancy
is deﬁned by the presence of metastases to a site where
pheochromocytoma/paraganglionic tissue is not normally
present, e.g. liver or bone, to avoid confusion with multiple
primary tumors. No single histological ﬁnding can predict
metastatic disease. However, patients with large tumor size (>5
cm), extra-adrenal location, or SDHB mutation have a higher
risk of malignancy.
Table 1. Diagnostic work-up for adrenal cancer
Hormonal work-up
Glucocorticoid excess (minimum 3 of 4 tests)
Dexamethasone suppression test (1 mg, 23:00 h)
Excretion of free urinary cortisol (24 h urine)
Basal cortisol (serum)
Basal ACTH (plasma)





17-beta-estradiol (serum, only in men and postmenopausal women)
24-h urine steroid metabolite examination
Mineralocorticoid excess
Potassium (serum)
Aldosterone/renin ratio (only in patients with arterial hypertension
and/or hypokalemia)
Catecholamine excess
Normetanephrine, metanephrine, and methoxytyramine (plasma)
Alternatively: fractionated metanephrine excretion (24 h urine)
Imaging
CT or MRI of abdomen and CT thorax
Bone scintigraphy (when suspecting skeletal metastases)
FDG-PET (optional)
MIBG scintigraphy, DOTA-TATE-PET, Dopa/Dopamine PET or
FDG-PET if pheochromocytoma is proved
Adapted according to the recommendation of the ACC working group of
the European Network for the Study of Adrenal Tumors (www.ensat.org/
acc.htm), May 2005.
In patients with a clearly established diagnosis of an ACC, one can skip
the workup on catecholamine excess (and conversely for established
pheochromocytoma, one can skip the steroid analysis). DHEA,
dehydroepiandrosterone.
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staging and risk assessment
The disease stage and margin-free resection are the most
important prognostic factors in ACC. In the assessment of the
disease stage, we recommend the tumor–node–metastasis
(TNM) classiﬁcation proposed by the ENSAT network
(Table 2) [9] (IV, A), since this system seems to be superior to
the staging system published by the Union Internationale
Contre le Cancer in 2004. Age, mitotic count, the proliferation
marker Ki67, and the glucocorticoid excess are additional
prognostic parameters to reﬁne the prognostic stratiﬁcation
[10]. New molecular markers for aggressiveness and survival
have been recently proposed, but their use in clinics needs
validation [11]. There is no staging system for malignant
pheochromocytoma and, in contrast to other neuroendocrine
tumors, no poorly differentiated category is recognized. The
survival rate depends mainly on the tumor size, primary tumor
location (extra-adrenal location is associated with poor
prognosis) [12], and the SDHB mutation status (SDHB
mutations are predictive of poor prognosis) [13]. The overall 5-
year survival rate is between 34% and 60%; however,
heterogeneous survival is a critical characteristic of this tumor
[12]. A signiﬁcant number of patients die of hormone-related
complications (increased blood pressure, constipation) [12].
management of local regional disease
Surgery is of utmost importance in the treatment of both ACC
and pheochromocytoma. Adrenal surgery should be performed
only in selected centers with >10 adrenalectomies for adrenal
cancer per year [14] (IV, A).
Open surgery with transperitoneal access is the standard
treatment of all patients with localized (stage I–II) and local
advanced stage (stage III) ACCs when complete resection can
be achieved. Laparoscopic adrenalectomy is a safe and effective
procedure for pheochromocytoma and a selected group of
patients with small ACCs (<8 cm) without preoperative
evidence for invasiveness and adrenal masses (e.g.
incidentalomas) that are judged as only potentially malignant.
This technique must be performed only in centers with a
consolidated experience in laparoscopic adrenal surgery, in
which principles of oncologic surgical treatment are strictly
respected [15] (IV, B).
The resection status (R0, R1, R2) is a major predictor of
prognosis for ACC. A margin-free complete resection (R0
resection), in fact, provides the only means to achieve long-
term survival [16] (V, A). To obtain an R0 resection of a
locally advanced ACC, it is often mandatory to resect (parts
of) adjacent organs such as the wall of the vena cava, liver,
spleen, colon, pancreas and/or stomach (V, B). Locoregional
lymphadenectomy improves tumor staging and seems to lead
to a favorable oncologic outcome [17] (IV, A). No data on the
prognostic role of radical surgery and lymphadenectomy are
available up to now for malignant pheochromocytoma.
For ACC tumors not invading the kidney, concomitant
nephrectomy seems not to improve disease-free and overall
survival and can be avoided, although additional data are
needed (V, B).
In the case of inoperable local inﬁltrating or metastatic ACC,
surgical excision of the primary tumor and/or metastasis
should be considered in case of an objective response after
neoadjuvant chemotherapy, when a radical resection seems to
be feasible [16].
Cytoreductive (R2) resection in malignant
pheochromocytoma may improve the quality of life and
survival by reducing the tumor burden and controlling
hormonal hypersecretion [2] (V, B). It is also indicated in
selected ACC patients with advanced tumors and severe
symptomatic hormone excess when medical therapy is not able
to control endocrine symptoms, and life expectancy is >6
months [18] (V, B).
Surgery for the recurrence of ACC (local and/or with a low
tumor metastatic burden) after primary treatment might be
effective in improving survival, if R0 resection is achievable and
the time to ﬁrst recurrence was >12 months (IV, B).
The hormone hypersecretion can increase the risk of
perioperative complications. For ACC patients, it is very
important to diagnose any adrenocorticotropic hormone
(ACTH)-independent glucocorticoid excess prior to surgery to
adopt measures to prevent a postoperative adrenal crisis or
insufﬁciency. In all patients with glucocorticoid excess
hydrocortisone must be administered during surgery (e.g. 150
mg/days) and postoperatively.
In patients with pheochromocytoma and secreting
paraganglioma, exposure to high levels of circulating
catecholamines during surgery could cause hypertensive crises
and arrhythmias. Therefore, all patients with
pheochromocytoma or paraganglioma should receive
preoperative preparation at least 10–14 days before surgery (V,
A) [19]. Blood pressure targets for the treatment are <130/80
mmHg in the supine position, and systolic blood pressure
preferably >90 mmHg in the upright position. Traditionally,
the non-competitive α-adrenoreceptor antagonist
phenoxybenzamine is frequently used. A standard dose is 10
mg twice daily with adjustments every 2–4 days. Alternatively
doxazosine, a competitive and selective α1-adrenoreceptor
antagonist might be as effective with fewer side effects. If the
target blood pressure is not reached, Ca-antagonists (nifedipine
slow release) or metyrosine may be used. Blockade of β-
adrenergic receptors is indicated in patients developing
tachyarrhythmias, but should never be started before the
blockade of α-receptors.
Hypertension during surgery may be treated with magnesium
sulfate, intravenous α-adrenoreceptor antagonist
(phentolamine), calcium antagonist, and/or nitroprusside or




I T1, N0, M0 Tumor ≤5 cm
II T2, N0, M0 Tumor >5 cm
III T1–T2, N1, M0 Lymph node involvement and/or
T3–T4, N0–N1, M0 tumor inﬁltration into surrounding
tissue and/or a tumor thrombus in
the vena cava and/or renal vein
IV T1–T4, N0–N1, M1 Metastatic disease
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nitroglycerine. Tachycardia can be treated with intravenous β-
adrenergic receptor blocker (esmolol). Postoperative hypotension
should be prevented by saline infusion the day before surgery. If
this adverse event occurs, it should be treated aggressively.
Postoperative care should also focus on glucose levels
because hypoglycemia may occur after the reduction of
catecholamine levels.
Most ACC patients have resectable disease at presentation,
however, more than half of the patients who have undergone
complete removal of the tumor are destined to have a relapse,
often with metastases [1]. Similarly, radical resection is not a
guarantee of cure for pheochromocytomas either. In one series
of 171 patients followed up after surgical resection of a
chromafﬁn cell tumor, 29 patients (17%) had recurrent or new
tumors, which were malignant in 15 (9%) cases [20].
The aggressive behavior and the high recurrence rate of ACC
provide the rationale for the use of adjuvant therapy. Adjuvant
radiotherapy to the tumor bed should be considered in patients
with incomplete/R1 resection or Rx resection [21] (V, A).
Mitotane has been the reference drug for the management of
ACC for decades. In a case control study involving 177 patients,
the outcome of 47 patients followed in Italian reference centers
that systematically adopted adjuvant mitotane to all radically
operated ACC was signiﬁcantly higher (in terms of both disease-
free survival and overall survival) than the outcome of 55 Italian
patients and 75 German patients followed in institutions not
administering adjuvant mitotane therapy [22].
Although these data cannot be considered conclusive, they
suggest that adjuvant mitotane can delay and possibly prevent
a recurrence of disease (V, B). On these bases, a panel of
international experts unanimously stated that patients with
potential residual disease (R1 or Rx resection) and/or Ki67
more than 10% should be offered adjuvant mitotane, whereas
adjuvant therapy was not considered mandatory in patients
fulﬁlling all of the following criteria: stage I or II disease,
histologically proven R0 resection; and Ki67 expressed in
≤10% of neoplastic cells [23] (V, B) (Figure 1A). For these
patients participation in the ﬁrst prospective multinational
randomized trial, testing the efﬁcacy of adjuvant mitotane
therapy (www.adiuvo-trial.org) is recommended whenever
possible. Mitotane is a difﬁcult drug to manage, with a long
half-life, dose-limiting toxicity, and a narrow therapeutic
window. Although the evidence is limited, the panel
recommends that the mitotane dosing should be guided by
plasma measurements, aiming at a concentration between 14
and 20 mg/ml since there is less antitumor activity <14 mg/ml
and the risk of toxicity (gastrointestinal and neurologic) is
higher above 20 mg/ml (V, A) [24]. A suggested mitotane
regimen is depicted in Table 3. Several blood analytes should
be monitored during mitotane therapy. Due to the adrenolytic
activity of mitotane, all patients must receive concomitant
administration of glucocorticoids to cover adrenal insufﬁciency.
Owing to an increased metabolic clearance rate of
glucocorticoids by mitotane therapy, high-dose glucocorticoid
replacement is needed. Mineralocorticoid supplementation is
necessary only in a subset of patients (Table 3). Testosterone
and thyroxine supplementation may be also required. Mitotane
can also induce a wide spectrum of hormone and metabolic
derangement and so an experienced endocrinologist should be
involved in the follow-up of patients during mitotane
treatment.
There are no data regarding the optimal duration of
adjuvant mitotane; we recommend that adjuvant mitotane
should be administered for at least 2 years since the greatest
frequency of disease recurrence is expected within this
timeframe. It is noteworthy that while mitotane is well
tolerated by a fraction of patients, the majority of patients ﬁnd
mitotane a difﬁcult therapy that markedly impacts the quality
of their lives. So the treatment duration should be assessed
individually, taking carefully into account the cost/beneﬁt ratio.
management of advanced/metastatic
disease
Prognosis in locally advanced inoperable and metastatic ACC
patients is poor, the 5-year overall survival being <15%.
However, recent studies have highlighted a greater
heterogeneity of advanced ACC than previously thought.
Extremely long survival has been reported in patients with
resectable oligometastatic disease with considerable intervals
among recurrences [10] (V, B).
Figure 1 Algorithm on management according to stage, risk factors, and
disease characteristics for adrenocortical carcinoma (ACC) (A) and
pheochromocytoma (B). *Low-risk ACC is deﬁned stage I–II and Ki67
expression in ≤10% of neoplastic cells, high-risk ACC: stage III or Ki67
expression in >10% of neoplastic cells.
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Mitotane is the only drug approved in locally advanced
inoperable and metastatic patients although randomized,
controlled prospective trials are lacking (IV, A). Response
rates vary between 13% and 35%, but many of these results
were derived from retrospective series since the 1960s with
variability in the response criteria [1, 10]. Patients with
long-term maintenance of mitotane levels in the therapeutic
range may obtain a survival beneﬁt [25]. Patients with
hormonal excess often experience clinical beneﬁt of this
strategy and continuation of mitotane treatment can be
indicated in these patients even after radiological progression
when alternative strategies to inhibit the hormonal excess are
lacking.
Owing to the latency of mitotane to attain the therapeutic
range, mitotane monotherapy is indicated in the management
of patients with a low tumor burden and/or more indolent
disease (Figure 1A). The combination with locoregional
therapies such as radiofrequency ablation (RFA) is
recommended. In case of rapidly progressing or life-
threatening extensive metastatic disease and/or radiological
progression under mitotane, cytotoxic chemotherapy is
indicated. Over the last 15 years, only 11 prospective single-
arm chemotherapy studies with a total of 239 patients with or
without mitotane have been published. Response rates vary
between 7% and 54%, again with variability in the response
criteria. The association of mitotane to chemotherapy seems to
be more active than chemotherapy alone [1], although no
randomized trials have formally demonstrated this superiority.
In the First International Randomized trial in advanced or
Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT
Table 3. Mitotane dose regimen, glucocorticoid, and mineralocorticoid supplementation, blood level monitoring, and dose adjustment according to toxicity
and blood level monitoring
Mitotane dose regimena • Start with 1.5 g/d and increase dose within 4–6 days to 6 g/days
• After 3 weeks, adjust dosage according tolerability and blood level (see below)
• Maximum dose 12 g/days, but most patients do not tolerate >8 g/days




• A total daily dose of 50 mg hydrocortisone (divided as 20–20–10 mg) or 75 mg cortisone acetate and
more may be needed. Glucocorticoid replacement is monitored best with careful clinical assessment




• Mitotane serum levels every 2–3 weeks in the ﬁrst 3 months. After reaching a plateau, the interval can
be extended (i.e. every 6 weeks)
• Glutamate-Oxaloacetate Transaminase (GOT), Glutamate-Pyruvate Transaminase (GPT), bilirubin,
Gamma-Glutamyl-Transferase (GGT). Initially every 4 weeks, after 6 months every 8 weeks. GGT is
invariably elevated without clinical consequences. If other liver enzymes are rapidly increasing (>3-fold
of baseline), there is a risk of liver failure: stop mitotane
• TSH, fT3, fT4 every 3–4 months. Thyroid hormone replacement is recommended in patients with
clinical symptoms of hypothyroidism
• Testosterone, free testosterone, and sexual hormone binding globulin (SHBG) should be tested in male
patients with symptoms of hypogonadism
• Renin every 3 months. If renin increases in the presence of symptoms suggestive of mineralocorticoid
deﬁciency, ﬂudrocortisones should be added
• Cholesterol (High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL)), triglycerides every 3–
4 months (in an adjuvant setting). If LDL/HDL cholesterol consistently increases, consider treatment
with statins not metabolized by CYP3A4 (e.g. pravastatin, rosuvastatin)
• Blood count every 3–4 months
Plasma mitotane level CNS (grade 2)/GI side effects (grade 3/4) Grade 3/4 CNS side effects
Absent Present Present
<14 mg/l Increase daily dose by 1 gb Reduce daily dose by 1 g Stop mitotanec
14–20 mg/l Maintain dose Reduce daily dose by 1.5 g Stop mitotanec
>20 mg/l Reduce daily dose to 50%–75% of the most
recent dose
Stop mitotanec Stop mitotanec
Recommended dose adjustment according to the central nervous system (CNS)/gastrointestinal (GI) side effects and plasma mitotane level. HDL, high-
density lipoprotein; LDL, low-density lipoprotein; GOT, glutamate-oxaloacetate transaminase; GPT, glutamate-pyruvate transaminase; GGT, gamma-
glutamyl-transferase.
aAn alternative low-dose regimen is also available with potentially similar efﬁcacy.
bup to the maximum tolerated dose.
cUntil symptom resolution (grade 0 or 1)
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trial), the two most active treatment regimens namely
Etoposide, Doxorubicin, Cisplatin, and Mitotane (EDP-M) and
Streptozotocin and Mitotane (Sz-M) were compared with 304
chemotherapy-naïve patients. Patients with disease progression
received the alternate regimen. The results of this trial, recently
published [26], indicate to us that EDP-M is the superior
regimen.
Although no statistically substantial increase in overall
survival was documented in patients receiving EDP-M as the
ﬁrst-line therapy, signiﬁcantly better response rates and
progression-free survival rates were achieved with EDP-M in
comparison with Sz-M. The rate of serious adverse events was
comparable. Of note, the results of the second-line regimens
replicated the rates observed with the ﬁrst-line therapy. Since
EDP-M was superior to Sz-M in terms of progression-free
survival either as ﬁrst-line or second-line therapy, the crossover
design may have attenuated its advantage on overall survival.
On these bases, we recommend EDP-M as the ﬁrst-line
therapy for ACC requiring cytotoxic therapy, and as the
reference for new therapies (I, A; Figure 1A).
In patients unﬁt for the EDP-M regimen P-M may
constitute a reasonable alternative [27]. However, the FIRM-
ACT trial with a median overall survival between 12 and 14.8
months clearly indicated that new systemic therapy options are
urgently needed, but thus far positive results are lacking
despite an increasing number of prospective studies, also
incorporating modern targeted agents. Results of studies with
oral CYP3A4-mediated drugs may have been hampered by
subtherapeutic systemic exposure due to CYP3A4 induction by
mitotane [28, 29]. A multicenter prospective randomized,
placebo-controlled clinical trial aimed to test the efﬁcacy of
OSI 906–301, an IGR inhibitor, as second-/third-line approach
in ACC patients has recently completed patient accrual.
However, the results of this study will not be available before
2013.
In case of painful metastasis, palliative radiotherapy is an
option, particularly in bone lesions (IV, B). Arterial
chemoembolization and radiofrequency ablation may be
beneﬁcial in selected patients (V, C).
The therapeutic strategy of metastatic pheochromocytoma/
paraganglioma aims to control excessive catecholamine
secretion and tumor burden, but no curative treatment is
achievable. Treatment choices include a wait and see policy,
locoregional therapies, systemic chemotherapy, and
radiopharmaceutical agents (Figure 1B) [2], and they should be
discussed case by case in a multidisciplinary specialized setting.
In the absence of any randomized studies and demonstrated
impact on survival, the patients’ quality of life should always be
considered. Indeed, due to the indolent course of subgroups of
patients, a wait and see policy coupled with a watchful follow-
up can be considered as an option in asymptomatic patients
with a low tumor burden. In these patients, an antineoplastic
treatment should be recommended in case of rapid progression
and/or symptom onset. In the absence of tumor progression,
surgery of the primary tumor or metastases can reduce
hormone secretion and may prevent complications related to a
critical anatomical location and improve the efﬁcacy of
subsequent therapies [2]. Metastatic disease palliation may also
beneﬁt from local therapy with embolization and or
radiofrequency ablation. Radionuclide therapy is an effective
treatment and 131I-MIBG, in activities ranging from 5.5 to 38
GBq (150–1000 mCi), is the most frequently used.
Approximately 50% of patients are eligible for 131I-MIBG
therapy based on the uptake on diagnostic scans. Several
studies have been published on the efﬁcacy of 131I-MIBG
treatment [2]; most are retrospective, and only one is a
prospective phase II study [30]. Objective responses were
observed in 22–47% of cases. Long-term survival of responders
of 4.7 years or 72 months was reported but progression at
study entry was not a prerequisite of most studies. Objective
responses were mainly observed in patients with soft tissue
metastases. Grade 3–4 toxicity was reported in 16%–83% of
patients.
131I-MIBG therapy should be considered as a ﬁrst-line
approach in patients with a good uptake of 123I-MIBG and
unresectable, progressive pheochromocytoma/paraganglioma
or symptomatic patients (not amenable to locoregional
control), or patients with a high tumor burden with a low
number of bone metastases. More recently peptide-
radiolabeled radiotherapy has also been developed.
Cyclophosphamide- and dacarbazine-based regimens
combined with vincristine (CVD) or doxorubicin (CVDD or
CDD) are the best studied chemotherapy regimens [2]. In the
largest published study to date (n = 52 patients), 40% of
patients treated with CVD, CDD, or CVDD experienced
clinical beneﬁts, including a reduction in tumor size in 25% of
cases [31]. Systemic chemotherapy is debated as a ﬁrst-line
therapy in patients with a low uptake of 123I-MIBG and
unresectable, rapidly progressive pheochromocytoma/
paraganglioma, or patients with high tumor burden or with a
high number of bone metastases. As in well-differentiated
pancreatic neuroendocrine tumors, there is a strong rationale
and some ﬁrst evidence on the potential efﬁcacy of anti-
angiogenic drugs in malignant pheochromocytomas. Thus, the
European ENSAT network is currently launching a
randomized, placebo-controlled trial testing sunitinib in
patients with malignant pheochromocytoma and
paraganglioma (FIRST-MAPPP trial).
follow-up
International recommendations on follow-up are lacking both
for ACC and pheochromocytoma/paraganglioma, and this is a
signiﬁcant problem. The recommendations in these guidelines
were formulated based on data available on the natural history
of these diseases, personal experience, and consensus among
panelists.
For patients with ACC after complete resection, we
recommend regular follow-up every 3 months including
abdominal CT (or MRI), thoracic CT, and monitoring of
initially elevated steroids (V, B). After 2 years, intervals may be
gradually increased. In case of long-term persistence of the
disease-free status, follow-up should be continued for at least
10 years.
For locally advanced or metastatic disease, overall survival
and time to progression (TTP) are the most important
endpoints with the response rate (RR) as a secondary end
point. The TTP and RR guide the clinical decision-making in
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an individual patient and should be evaluated at regular
intervals (every 12 weeks or less depending on the therapy)
using CT scans. The role of PET scans is not yet clear in ACC.
Patients who underwent successful surgery for non-
metastatic pheochromocytoma/paraganglioma are at risk of
malignant recurrence and require long-term clinical
(adrenergic symptoms and blood pressure levels) and
biochemical (plasma or urinary metanephrine,
normetanephrine, chromogranin A, and methoxythyramine)
follow-up [2]. The follow-up is especially important for
patients with extra-adrenal primary disease, tumor size >5 cm,
or SDHB mutations. Biochemical testing is repeated ∼14 days
following surgery to check for remaining disease and thereafter
every 3–4 months for 2–3 years. This should subsequently be
repeated every 6 months. Patients with new events (high blood
pressure, adrenergic symptoms, or pain) or pathological
endocrine tests and/or elevated circulating chromogranin A
should undergo imaging that includes thorax and abdomen CT
and best functioning imaging (PET FDG in most cases). In
case of proven malignant disease, SDHB mutation, extra-
adrenal primary disease, and in rare cases of
pheochromocytoma/paraganglioma without relevant
preoperative hormone secretion, imaging could be repeated at
least every 6 months during the ﬁrst year and yearly afterward,
irrespective of the negative results of biochemical tests. In these
patients, lifelong follow-up is recommended [2].
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